ReNeuron Group (LON:RENE) Stock Price Passes Above 50 Day Moving Average of $27.62

Shares of ReNeuron Group plc (LON:RENEGet Rating) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 27.62 ($0.33) and traded as high as GBX 28.50 ($0.34). ReNeuron Group shares last traded at GBX 28.50 ($0.34), with a volume of 104,785 shares.

ReNeuron Group Stock Performance

The firm’s 50 day simple moving average is GBX 27.62 and its 200 day simple moving average is GBX 31.31. The company has a current ratio of 2.35, a quick ratio of 2.29 and a debt-to-equity ratio of 5.68. The firm has a market cap of £16.19 million and a PE ratio of -1.55.

Insider Activity

In other ReNeuron Group news, insider Barbara Staehelin bought 127,000 shares of the firm’s stock in a transaction dated Tuesday, July 12th. The shares were purchased at an average cost of GBX 30 ($0.36) per share, for a total transaction of £38,100 ($46,036.73). In other news, insider Barbara Staehelin purchased 127,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 12th. The shares were bought at an average cost of GBX 30 ($0.36) per share, for a total transaction of £38,100 ($46,036.73). Also, insider Iain G. Ross purchased 30,000 shares of the business’s stock in a transaction that occurred on Friday, September 2nd. The shares were purchased at an average price of GBX 26 ($0.31) per share, for a total transaction of £7,800 ($9,424.84).

About ReNeuron Group

(Get Rating)

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate that is in the partnering stage in china and outside china for treating stroke disability; and human retinal progenitor cell therapy that is in Phase I/IIa clinical trial for treating retinitis pigmentosa, a blindness-causing disease.

Further Reading

Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.